TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.91 million.

At June 30, 2017, cash on hand was approximately $96.5 million, compared with approximately $131.5 million at December 31, 2016.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.